Comparative Pharmacology
Head-to-head clinical analysis: SULFAPYRIDINE versus SULFATRIM PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAPYRIDINE versus SULFATRIM PEDIATRIC.
SULFAPYRIDINE vs SULFATRIM PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
Sulfamethoxazole inhibits dihydropteroate synthase, blocking bacterial folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade leads to bactericidal activity.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
Sulfatrim Pediatric suspension contains sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL. For patients >40 kg, dose is 800 mg SMX/160 mg TMP orally every 12 hours for 10-14 days.
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Sulfamethoxazole: 9-11 hours; Trimethoprim: 8-10 hours; prolonged in renal impairment (e.g., CrCl <30 mL/min).
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Renal: 50-70% of total sulfamethoxazole (SMX) and 30-50% of total trimethoprim (TMP) are excreted unchanged in urine; the remainder as metabolites; biliary/fecal excretion is minimal.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic